{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:23Z","timestamp":1789940063745,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.jbspin.2011.12.004","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T21:12:50Z","timestamp":1327957970000},"page":"365-369","source":"Crossref","is-referenced-by-count":34,"title":["Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections"],"prefix":"10.1016","volume":"79","author":[{"given":"Anne","family":"Isvy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Gobeaux-Chenevier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Wipff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Job-Deslandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2011.12.004_bib0005","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2010.134684","article-title":"State-of-the-art: rheumatoid arthritis","volume":"69","author":"McInnes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B\u00a0lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B\u00a0lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","article-title":"New drugs for aggressive B-cell and T-cell lymphomas","volume":"11","author":"Murawski","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0025","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jbspin.2008.02.009","article-title":"Rituximab: a new therapeutic alternative in rheumatoid arthritis","volume":"75","author":"Sibilia","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0030","first-page":"31","article-title":"Rituximab therapy in rheumatoid arthritis in daily practice","volume":"35","author":"Assous","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0035","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab (AIR) registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0040","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated\u00a0B lymphocyte depletion with rituximab in rheumatoid arthritis over 7\u00a0years","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jbspin.2010.01.008","article-title":"Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30\u00a0cases in everyday practice","volume":"77","author":"Toussirot","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/152581603321210082","article-title":"Long-lasting hypogammaglobulinemia following rituximab administration for Epstein\u2013Barr virus-related post-transplant lymphoproliferative disease preemptive therapy","volume":"12","author":"Castagnola","year":"2003","journal-title":"J Hemato Ther Stem Cell Res"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","article-title":"B-cell depletion for 2\u00a0years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period","volume":"49","author":"Lim","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"LimSH","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0065","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77\u00a0treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0095","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalization with infection among Swedish\u00a0RA patients treated with TNF\u00a0antagonist","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0100","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0070","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0075","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled phase\u00a0III trial evaluating primary efficacy and safety at 24\u00a0weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0080","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase\u00a0IIB randomized, double-blind, placebo-controlled, dose ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0090","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0125","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/ard.2008.101675","article-title":"Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients","volume":"68","author":"Genovese","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0130","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0105","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0110","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2011.12.004_bib0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.30152","article-title":"Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B\u00a0cell depletion","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X11002910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X11002910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T14:22:26Z","timestamp":1543242146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X11002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1297319X11002910"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2011.12.004","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}